FDA approves Elusys' Anthim for inhalational anthrax

FDA approved Anthim obiltoxaximab from Elusys Therapeutics Inc. (Pine Brook, N.J.) to treat inhalational anthrax in combination with antibacterial drugs, and to prevent inhalational anthrax when alternative therapies are not available or are inappropriate. Anthim was approved under FDA's Animal Rule.

Anthim is a high-affinity humanized mAb against the Bacillus anthracis protective antigen that inhibits binding of anthrax toxins. ...